SCHEMBL583045

SCHEMBL583045

Cc1nc(C)c(COc2ccc(C=CC(=O)O)cc2)nc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.52
PPARA Q07869 2/20 0.52
THRB P10828 1/20 0.51
ATM Q13315 1/20 0.51
PPARG P37231 1/20 0.48
GSK3B P49841 2/20 0.47
BACE1 P56817 2/20 0.47
TBXAS1 P24557 2/20 0.45
CA12 O43570 1/20 0.45
AKR1B10 O60218 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
ESR1 P03372 1/20 0.45
CA3 P07451 1/20 0.45
PKM P14618 1/20 0.45
TYR P14679 1/20 0.45
AKR1B1 P15121 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
DPP4 P27487 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583043 1.00 PPARD (0.52) PPARDPPARATHRBATMPPARG
SCHEMBL583567 0.86 CA12 (0.58) CA12CA1CA2DPP4CA7
SCHEMBL13143817 0.86 CA12 (0.58) CA12CA1CA2DPP4CA7
SCHEMBL583568 0.86 CA12 (0.58) CA12CA1CA2DPP4CA7
SCHEMBL28163988 0.85 ALDH1A1 (0.63) THRBESR1PKMESR2
SCHEMBL582919 0.80 KDM4E (0.64) CA2CA5ACA9
SCHEMBL582918 0.80 KDM4E (0.64) CA2CA5ACA9
SCHEMBL28164576 0.76 PTGER4 (0.60) ATM
SCHEMBL691132 0.75 NPC1 (0.69) THRBATMPOLB
SCHEMBL691131 0.75 NPC1 (0.69) THRBATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350033-B2 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) 2013-01-08 US disclosed
EP-2213666-B1 LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION LI JIAMING (CN) 2012-02-15 EP disclosed
US-20100228029-A1 Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) 2010-09-09 US disclosed
EP-2213666-A1 LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION Li, Jiaming (CN) 2010-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228029-A1 Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application AHR, CYP3A5, CYP3A43 PPARD 147/4885PPARA 77/4885THRB 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.